| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRTX | Common Stock | Sale | -$1.83M | -4.36K | -16.19% | $419.04 | 22.6K | Feb 14, 2024 | Direct | F1, F2, F3 |
| transaction | VRTX | Common Stock | Sale | -$1.95M | -4.66K | -20.64% | $419.16 | 17.9K | Feb 15, 2024 | Direct | F1 |
| holding | VRTX | Common Stock | 440 | Feb 14, 2024 | 401(k) |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023. |
| F2 | Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| F3 | Open market sales reported on this line occurred at a weighted average price of $419.04 (range $419.00 to $419.38). |